MX2010002053A - Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. - Google Patents
Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.Info
- Publication number
- MX2010002053A MX2010002053A MX2010002053A MX2010002053A MX2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A MX 2010002053 A MX2010002053 A MX 2010002053A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- treating
- treatment
- compositions
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Esta invención proporciona una proteína de fusión que comprende un péptido de señalización, un dominio extracelular receptor de una proteína de Notch humana y una porción Fc de un anticuerpo enlazado ahí. Esta invención también proporciona un método para tratar a un sujeto que tiene un tumor, un método para inhibir la angiogénesis en un sujeto, un método para tratar a un sujeto que tiene cáncer ovárico y un método para tratar a un sujeto que tiene un desorden metabólico, que comprende administrar al sujeto una cantidad efectiva de la proteína de fusión antes mencionada para tratar al sujeto. Esta invención además proporciona usos de la proteína de fusión de arriba para la preparación de una composición farmacéutica para el tratamiento de un sujeto que tiene un tumor, para inhibir la angiogénesis en un sujeto, para tratar a un sujeto que tiene cáncer ovárico y para tratar a un sujeto que tiene un desorden metabólico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96605207P | 2007-08-23 | 2007-08-23 | |
PCT/US2008/010045 WO2009025867A2 (en) | 2007-08-23 | 2008-08-22 | Compositions of humanized notch fusion proteins and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010002053A true MX2010002053A (es) | 2010-07-28 |
Family
ID=40378882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010002053A MX2010002053A (es) | 2007-08-23 | 2008-08-22 | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9127085B2 (es) |
EP (1) | EP2193143B1 (es) |
JP (2) | JP2010536855A (es) |
KR (1) | KR20100076947A (es) |
CN (1) | CN101883786A (es) |
AU (1) | AU2008289462B2 (es) |
BR (1) | BRPI0815291A2 (es) |
CA (1) | CA2697262A1 (es) |
IL (2) | IL204111A (es) |
MX (1) | MX2010002053A (es) |
NZ (3) | NZ618129A (es) |
RU (1) | RU2532830C2 (es) |
SG (1) | SG183763A1 (es) |
WO (1) | WO2009025867A2 (es) |
ZA (1) | ZA201001427B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
WO2011053822A2 (en) * | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
WO2007103114A2 (en) | 2006-03-07 | 2007-09-13 | The Brigham & Women's Hospital, Inc. | Notch inhibition in the treatment or prevention of atherosclerosis |
CA2655362A1 (en) | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
WO2009103637A1 (en) * | 2008-02-22 | 2009-08-27 | Vrije Universiteit Brussel | Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells |
NZ590131A (en) | 2008-07-08 | 2012-10-26 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
EP2326345B1 (en) | 2008-08-22 | 2015-01-14 | The Trustees of Columbia University in the City of New York | Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling |
MX2012008085A (es) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Agentes de union notch1 y metodos de uso de los mismos. |
TW201329105A (zh) * | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類notch1引誘物 |
ES2744267T3 (es) | 2012-11-21 | 2020-02-24 | Pharmabcine Inc | Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo |
US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
WO2014151950A1 (en) * | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver |
US20160030513A1 (en) * | 2013-03-15 | 2016-02-04 | The Trustees Of Columbia University In The City Of New York | Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver |
ES2818184T3 (es) * | 2015-04-16 | 2021-04-09 | Eisai R&D Man Co Ltd | Anticuerpo anti-Notch 4 humano |
US11026996B2 (en) | 2016-05-25 | 2021-06-08 | The Trustees Of Columbia University In The City Of New York | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling |
US11325957B2 (en) * | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
CN108753833B (zh) * | 2018-05-28 | 2021-12-03 | 上海海洋大学 | 斑马鱼notch3基因突变体的制备方法 |
CN109467598B (zh) * | 2018-11-28 | 2021-11-09 | 生命谷(海南)生物科技股份有限公司 | 肿瘤相关基因notch1突变短肽及其应用 |
US20230174633A1 (en) * | 2020-03-30 | 2023-06-08 | Memorial Sloan Kettering Cancer Center | Methods and compositions for modulating lipid storage in adipose tissue |
CN112961250B (zh) * | 2021-03-01 | 2023-06-06 | 长春金赛药业有限责任公司 | 抗体融合蛋白及其应用 |
CN114062682A (zh) * | 2021-11-10 | 2022-02-18 | 厦门大学附属心血管病医院 | Notch3作为检测靶标的应用 |
CN116790603B (zh) * | 2023-08-18 | 2023-10-31 | 成都中科奥格生物科技有限公司 | 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
IE20030749A1 (en) * | 1991-05-03 | 2003-11-12 | Indiana University Foundation | Human notch and delta binding domains in torporythmic proteins, and methods based thereon |
US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
FR2751986B1 (fr) | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
GB9623236D0 (en) * | 1996-11-07 | 1997-01-08 | Imperial College | Notch |
US6379925B1 (en) * | 1997-06-18 | 2002-04-30 | The Trustees Of Columbia University In The City Of New York | Angiogenic modulation by notch signal transduction |
US6703221B1 (en) | 1999-08-19 | 2004-03-09 | Chiron Corporation | Notch receptor ligands and uses thereof |
GB9927328D0 (en) | 1999-11-18 | 2000-01-12 | Lorantis Ltd | Immunotherapy |
US6689744B2 (en) * | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
WO2003042246A2 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
EP1492816A2 (en) * | 2002-04-05 | 2005-01-05 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
AU2003255735A1 (en) | 2002-08-03 | 2004-02-23 | Lorantis Limited | Conjugate of notch signalling pathway modulators and their use in medical treatment |
AU2003267563A1 (en) * | 2002-09-10 | 2004-04-30 | Lorantis Limited | Pharmaceutical composition and medical treatments comprising notch ligand proteins |
WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
WO2006047878A1 (en) | 2004-11-03 | 2006-05-11 | British Columbia Cancer Agency Branch | Cancer therapeutics and methods for their use |
CN101277672A (zh) * | 2005-07-29 | 2008-10-01 | 通用医疗公司 | 用于减少皮肤损伤的方法和组合物 |
BRPI0715989A8 (pt) | 2006-10-19 | 2018-03-13 | Genentech Inc | "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" |
EP2326345B1 (en) | 2008-08-22 | 2015-01-14 | The Trustees of Columbia University in the City of New York | Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling |
TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類notch1引誘物 |
-
2008
- 2008-08-22 CN CN2008801120573A patent/CN101883786A/zh active Pending
- 2008-08-22 AU AU2008289462A patent/AU2008289462B2/en not_active Ceased
- 2008-08-22 NZ NZ618129A patent/NZ618129A/en not_active IP Right Cessation
- 2008-08-22 BR BRPI0815291 patent/BRPI0815291A2/pt not_active IP Right Cessation
- 2008-08-22 SG SG2012062477A patent/SG183763A1/en unknown
- 2008-08-22 NZ NZ583649A patent/NZ583649A/en not_active IP Right Cessation
- 2008-08-22 CA CA 2697262 patent/CA2697262A1/en not_active Abandoned
- 2008-08-22 US US12/733,329 patent/US9127085B2/en not_active Expired - Fee Related
- 2008-08-22 RU RU2010110812/10A patent/RU2532830C2/ru not_active IP Right Cessation
- 2008-08-22 WO PCT/US2008/010045 patent/WO2009025867A2/en active Application Filing
- 2008-08-22 KR KR20107006041A patent/KR20100076947A/ko not_active Application Discontinuation
- 2008-08-22 MX MX2010002053A patent/MX2010002053A/es active IP Right Grant
- 2008-08-22 JP JP2010521897A patent/JP2010536855A/ja active Pending
- 2008-08-22 NZ NZ60017108A patent/NZ600171A/en not_active IP Right Cessation
- 2008-08-22 EP EP08795559.7A patent/EP2193143B1/en active Active
-
2010
- 2010-02-23 IL IL204111A patent/IL204111A/en not_active IP Right Cessation
- 2010-02-26 ZA ZA2010/01427A patent/ZA201001427B/en unknown
-
2012
- 2012-07-02 IL IL220723A patent/IL220723A0/en unknown
-
2015
- 2015-08-07 JP JP2015157312A patent/JP2016040245A/ja active Pending
- 2015-09-03 US US14/844,642 patent/US20160115217A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG183763A1 (en) | 2012-09-27 |
ZA201001427B (en) | 2011-05-25 |
EP2193143A4 (en) | 2012-01-25 |
US9127085B2 (en) | 2015-09-08 |
NZ618129A (en) | 2015-05-29 |
CA2697262A1 (en) | 2009-02-26 |
IL220723A0 (en) | 2012-08-30 |
WO2009025867A3 (en) | 2009-12-30 |
KR20100076947A (ko) | 2010-07-06 |
NZ600171A (en) | 2014-01-31 |
WO2009025867A2 (en) | 2009-02-26 |
EP2193143B1 (en) | 2016-06-08 |
NZ583649A (en) | 2012-06-29 |
RU2532830C2 (ru) | 2014-11-10 |
US20110008342A1 (en) | 2011-01-13 |
US20160115217A1 (en) | 2016-04-28 |
CN101883786A (zh) | 2010-11-10 |
IL204111A (en) | 2015-08-31 |
AU2008289462A1 (en) | 2009-02-26 |
JP2010536855A (ja) | 2010-12-02 |
AU2008289462B2 (en) | 2014-01-23 |
EP2193143A2 (en) | 2010-06-09 |
RU2010110812A (ru) | 2011-09-27 |
JP2016040245A (ja) | 2016-03-24 |
BRPI0815291A2 (pt) | 2015-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010002053A (es) | Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento. | |
MX2011001805A (es) | Proteinas de fusion humanas basadas en notch3 como inhibidores de señuelo de la señalizacion de notch3. | |
NZ590131A (en) | Notch-binding agents and antagonists and methods of use thereof | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
WO2008091641A3 (en) | Compositions and methods for diagnosing and treating cancer | |
WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
WO2007145840A3 (en) | Compositions and methods for diagnosing and treating cancer | |
NZ607710A (en) | 4-1bb binding molecules | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
WO2010019702A3 (en) | Ddr1-binding agents and methods of use thereof | |
EA201792376A3 (ru) | Молекулы анти-gcc антитела и соответствующие композиции и способы | |
EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
MX355181B (es) | Anticuerpos humanos contra el factor tisular. | |
UA117807C2 (uk) | ІМУНОКОН'ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ | |
MA32288B1 (fr) | Nouveaux anticorps utiles pour le traitement du cancer | |
WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
WO2008142303A3 (fr) | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer | |
WO2011063237A3 (en) | Jagged-binding agents and uses thereof | |
SI2125897T1 (en) | MONOCOLONIAL PROTITELES AGAINST GT 468 FOR CARRYING CANCER | |
WO2008070090A3 (en) | Compositions and methods for diagnosing and treating cancer | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |